Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed the stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 4-day suspension order on a drug license for a single store located at Addagutta East Marredpally in Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Secunderabad, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on July 18, 2025. The company has estimated a potential revenue loss of approximately Rs 0.82 lakhs from this suspension. The disclosure is being made under SEBI Listing Regulations to keep the market informed of the regulatory action.
The impact is negligible — a single store out of Medplus's large retail network faces a 4-day suspension with a revenue impact of less than Rs 1 lakh, and is unlikely to affect the company's overall operations, earnings, or stock price in any meaningful way.